Since the first AMI patient was treated with CRP-apheresis 8 years ago, it has been successfully and safely used in patients suffering from AMI, acute necrotizing pancreatitis, Crohn’s disease, COVID-19, stroke and after bypass surgery. This evidence concerns the gene CRP and COVID-19.